Core Insights - Ginkgo Bioworks reported a total revenue of $33 million for Q4 2025, a decrease of 24% compared to $44 million in Q4 2024, with Biosecurity revenue at $7 million and Cell Engineering revenue at $26 million, down 30% and 26% respectively [1] - For the full year 2025, total revenue was $170 million, down 25% from $227 million in 2024, primarily due to a shift from early-stage customers to larger enterprise clients [1] - The company announced a strategic focus on autonomous labs and plans to divest its non-core biosecurity business, which will operate as a standalone entity [1] Financial Performance - Q4 2025 total revenue was $33 million, down from $44 million in Q4 2024, with Biosecurity revenue decreasing from $9 million to $7 million and Cell Engineering revenue decreasing from $35 million to $26 million [1] - Full year 2025 total revenue was $170 million, down from $227 million in 2024, with Cell Engineering revenue at $133 million, down from $174 million, and Biosecurity revenue at $37 million, down from $53 million [1] - The company ended 2025 with $423 million in cash, cash equivalents, and marketable securities, indicating a strong cash position despite the revenue decline [1] Strategic Focus - Ginkgo plans to invest in autonomous labs, aiming to demonstrate capabilities by consolidating its R&D services into a single large autonomous lab [1] - The company is expanding its frontier autonomous lab in Boston to include over 50 Reconfigurable Automation Carts (RACs), with an additional 50 expected by year-end [1] - Ginkgo has secured a $47 million contract for a 97-instrument autonomous lab and has collaborated with OpenAI to improve experiment design, achieving a 40% improvement in Cell-Free Protein Synthesis [1] Business Divestiture - Ginkgo has reached an agreement to sell its biosecurity business to a consortium of investors, allowing it to operate as a standalone entity while Ginkgo retains a minority equity position [1] - This divestiture is expected to provide the biosecurity business with greater flexibility and resources for growth, while Ginkgo can focus its investments on the autonomous labs business [1] 2026 Outlook - Ginkgo anticipates a total cash burn of $(150) million to $(125) million in 2026 as it continues to invest in its autonomous labs [1]

Core Insights - Meta has invested over $70 billion in its VR and metaverse initiatives since 2020, but the growth of the industry has been slower than anticipated, leading to recent cuts in its Reality Labs division [1][2] - The company has acknowledged that its vision for Horizon and VR was overly ambitious, resulting in a need to scale back on several VR products, including virtual workplace and fitness applications [2][3] - Despite the setbacks, Meta remains optimistic about the future of VR, claiming to invest more in content than any competitor [2][3] Investment Strategy - Meta's CTO stated that the current investment exceeds the growth potential of the VR ecosystem, indicating a significant loss and a need for emotional acknowledgment of the situation [2][5] - The company continues to view itself as a net positive investor in the VR ecosystem, even after scaling back its ambitions [3][4] - There is a belief that the challenges faced in VR do not necessarily detract from the potential growth in wearables, as both can be pursued simultaneously [3][4] Future Outlook - The CTO has previously indicated that 2025 will be a critical year for the metaverse, determining whether Meta's efforts will be seen as visionary or a misadventure [4] - There is a cautious tone regarding future investments, with the company emphasizing the need for its investment levels to align with actual growth [5]

RT Horizon (@JoinHorizon)Bitcoin is down ~50% from the highs.Volatility is part of bitcoin. Liquidation risk doesn't have to be.In this video, we compare bitcoin-backed loans, HELOCs, and Horizon using the same criteria. https://t.co/6uQye13R1Y ...

Core Viewpoint - Meta Platforms is focusing on its smart glasses business and aims to achieve profitability in its VR ecosystem in the coming years, with significant investments directed towards eyewear and wearable devices [1][3]. Group 1: Financial Performance and Strategy - Meta reported a revenue of $2.207 billion for Reality Labs in 2025, with a loss of $19.2 billion [1]. - The company has laid off over 1,000 employees in Reality Labs, closed three VR studios, and halted the sale of enterprise Quest headsets and related services [3]. - CEO Mark Zuckerberg indicated that the significant losses in Reality Labs are nearing a turning point, with expectations of reduced losses as the company focuses on AI wearable devices [3]. Group 2: Product Development and Market Position - The sales of Meta's smart glasses grew threefold last year, making them one of the fastest-growing consumer electronics products in history [3]. - Zuckerberg believes that AI glasses will eventually replace traditional eyewear, similar to how smartphones replaced flip phones, emphasizing that it is only a matter of time [3]. - Future plans for the glasses include features that allow them to see and hear what the user does, providing assistance in daily life and displaying information directly in the user's field of vision [3]. Group 3: Competitive Landscape - Meta remains the fastest-moving company in the smart glasses market, but competition is expected to intensify with Google launching a smart glasses product line this year and Apple planning to release its own within the next 1-2 years [4]. - Snap has announced the separation of its AR glasses Specs team into a new subsidiary to enhance business focus [4].

Core Insights - Meta has laid off 10% of its Reality Labs staff, approximately 1,000 employees, amid significant financial losses in its virtual reality unit [1] - The Reality Labs unit reported a loss of $19.1 billion in 2025, slightly higher than the $17.7 billion loss in 2024, with a fourth-quarter loss of $6.2 billion [2] - CEO Mark Zuckerberg expressed optimism for the VR team but indicated that losses in 2026 are expected to remain similar to those in 2025 [3] Financial Performance - Reality Labs generated $955 million in sales during Q4 and approximately $2.2 billion throughout 2025, against substantial losses [2] - The company anticipates that losses for Reality Labs will peak in the current year, with a gradual reduction expected in the future [4] Strategic Direction - Meta is shifting its investment focus towards glasses and wearables while aiming to make Horizon a success on mobile platforms [4] - The company plans to close several VR studios and retire its standalone Workrooms app, indicating a declining interest in virtual reality [5]

Core Insights - Meta's Reality Labs, its virtual reality unit, has faced significant financial losses, totaling approximately $19.1 billion in 2025, which is an increase from $17.7 billion in 2024 [2] - The company has laid off 10% of its Reality Labs staff, equating to around 1,000 employees, as part of a broader strategy to address ongoing losses [1] Financial Performance - In 2025, Reality Labs generated $2.2 billion in sales, with $955 million in Q4 alone, while incurring a loss of $6.2 billion in the same quarter [2] - Losses for Reality Labs are expected to remain consistent in 2026, with Zuckerberg indicating that this year may represent a peak in losses before a gradual reduction [3][4] Strategic Direction - Meta is shifting its investment focus towards glasses and wearables, aiming to make its Horizon platform successful on mobile and establish a profitable VR ecosystem [4] - The company plans to close several VR studios and retire its standalone Workrooms app, signaling a diminishing interest in virtual reality [5]

RT Horizon (@JoinHorizon)HELOC: Monthly payments, interest charges, credit checks, term limitsHorizon: Zero monthly payments, zero interest, no credit impact, no timeline pressureSame equity unlock. Completely different structure.Built by Bitcoiners, for Bitcoiners 🫡 ...

Core Insights - The US Securities and Exchange Commission (SEC) has officially closed its nearly four-year investigation into the DeFi protocol Aave without taking enforcement action [2][3] - Aave's founder, Stani Kulechov, has shared a long-term roadmap focusing on scaling the platform into a core credit system of the onchain economy [4] Regulatory Developments - The investigation began under the Biden administration, reflecting a tougher regulatory stance on digital assets [3] - Aave Labs maintained regular communication with regulators throughout the investigation, allowing for operations without legal uncertainty [3] Aave's Long-Term Strategy - The roadmap includes three main areas: Aave V4, Horizon, and the Aave App, aiming to onboard millions of new users and move the next trillion dollars in assets onchain [4] - Aave has processed over $3.33 trillion in total deposits and issued nearly $1 trillion in loans since its launch [4] Financial Performance - In the current year, Aave generated approximately $885 million in fees and holds about 59% of the DeFi lending market [5] - Despite its size, Kulechov describes Aave as still being in its early stages [5] Product Developments - Aave V4 will redesign the protocol's structure to unify liquidity across different networks [5] - Horizon, launched earlier this year, focuses on regulated and compliance-aligned lending [5] - The Aave App aims to simplify access to DeFi for everyday users [6] Market Reaction - AAVE's price has seen a short-term decline of around 2%, with trading volume dropping by approximately 28% [7] - The token is currently trading below a major resistance zone, with a key support area identified between $135 and $150 [7]

Aave's Future Strategy - Aave founder Stani Kulechov reveals the 2026 master plan [1] - The plan includes Aave V4, Horizon for institutional RWAs (Real World Assets), and Aave App [1] Aave's Ambition - Aave aims to "win" in the market [1]

Summary of the Conference Call Company Overview - The conference is hosted by Piper Sandler, focusing on the healthcare sector, with a specific emphasis on Natera, a diagnostics company specializing in genetic testing and oncology solutions [1][2]. Key Highlights from Natera's Performance - Natera reported a record revenue performance in Q3, surpassing $500 million for the first time in the company's history [3][4]. - The company achieved a gross margin of 64.9%, with an adjusted gross margin of 61.3%, both of which are records for Natera [3][4]. - Clinical signature units exceeded 20,000 in the quarter, contributing to a total of 200,000 clinical units overall [3][4]. Growth Projections - Natera anticipates that its Minimal Residual Disease (MRD) business will exceed $1 billion in revenue within the next two to three years, with current growth rates in the double digits [2][4]. - The company is focusing on absolute growth units rather than growth rates, aiming to maintain stable average selling prices (ASPs) for Women's Health and Organ Health segments [5][6]. Business Segments Performance - Women's Health has shown significant ASP improvements, with current prices for Non-Invasive Prenatal Testing (NIPT) being higher than they were a decade ago [6][7]. - Organ Health is experiencing strong growth, particularly in cell-free DNA testing, which is expected to replace traditional tissue biopsies over time [9][10]. - The oncology segment is still in early stages of market penetration, with expectations of continued growth in MRD volume due to high unmet needs [10][11]. Reimbursement and Coverage - Natera has established itself as a large in-network lab for major payers, facilitating coverage for Medicare Advantage patients [18][19]. - The company is actively working on expanding coverage for various tumor types, with seven submissions ready for the MolDX program to enhance reimbursement opportunities [21][23]. Clinical Trials and Research - The IMvigor trial demonstrated a 41% improvement in overall survival for muscle-invasive bladder cancer patients treated with atezolizumab, highlighting the efficacy of Natera's Signatera test [24][26]. - The company is preparing for the FIND study in 2027, which aims to evaluate the performance of its tests in advanced adenomas [34][35]. Market Dynamics and Competitive Landscape - Natera is leveraging its strong data and clinical utility to negotiate pricing and contracts with payers, ensuring a collaborative relationship that emphasizes the savings generated for the healthcare system [20][22]. - The company is exploring additional clinical questions and opportunities alongside its Signatera test, particularly in the context of tissue genomics [30][32]. Conclusion - Natera is positioned for strong growth across its business segments, with a focus on expanding its market presence, enhancing reimbursement strategies, and continuing to deliver innovative diagnostic solutions [12][12].